Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05909683 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Assessing the Procalcitonin-guidance and Molecular-guided Diagnosis for Therapy of Severe Infections (the MODIFY Trial)

Study acronym: MODIFY
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 16, 2026 (before its estimated April 15, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruiting
    • Primary and study completion dates: Dec 27, 2026 to Apr 15, 2026
    • Site details revised at 15 of 15 sites
    v11
  2. Primary and study completion dates: Jul 25, 2025 to Dec 27, 2026
    • Study sites: 12 to 15
    • Start date: Sep 14, 2023 to Sep 19, 2023
    v10
  3. Site details revised at 1 of 12 sitesv9
  4. Site details revised at 1 of 12 sitesv8
  5. Site details revised at 2 of 12 sitesv7
Show 5 earlier versionsHide 5 earlier versions
  1. Study sites: 9 to 12v6
  2. Site details revised at 1 of 9 sitesv5
  3. Site details revised at 1 of 9 sitesv4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 9
    • Primary and study completion dates: Jul 2025 to Jul 25, 2025
    • Start date changed from estimate of Jul 2023 to Sep 14, 2023
    v3
  5. Secondary endpoints revised (11)v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
MODIFY is a randomized, open-labeled, and prospective study that will be conducted in multiple Intensive Care Units (ICUs) and departments of Internal Medicine across Greece. It aims to change the traditional approach for the management of severe infections by integrating the results of BCID2, Reveal Rapid AST, and PCT, to improve patients' outcomes. Early and precise identification of the underlying causative pathogen along with the fast acquisition of the antimicrobial sensitivity results may positively impact the uncontrolled antimicrobial prescription.
Trial Details
NCT Number NCT05909683
Lead Sponsor Hellenic Institute for the Study of Sepsis
Conditions
(from sponsor)		 Sepsis
Related terms Infections, Sepsis
Enrollment 190 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov